MedPage Today July 11, 2021
— Exorbitant drug pricing and inaccessible care require government intervention
Walmart just announced a new low-priced insulin for patients with diabetes.
Is this good news?
Yes, for some patients. Walmart already offers an older formulation of human insulin, ReliOn Novolin, for $25 per vial. Adding a low-cost rapid-acting analog insulin — ReliOn Novolog — to the Walmart ReliOn brand should help patients who are better treated with this modern analog insulin and who would otherwise be paying the full list price.
Yet, this lower cost option is not enough to fully address the issue of insulin affordability and it highlights the systemic problems we face in the U.S. regarding the high costs of needed prescription drugs.
This is still too...
Today's Sponsors
Today's Sponsor